ribavirin has been researched along with losartan potassium in 90 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 58 (64.44) | 29.6817 |
| 2010's | 32 (35.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Dieterich, DT; Hau, T; Kreiswirth, S; Talal, AH; Weisz, K | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lafarge, P; Lunel-Fabiani, F | 1 |
| Dieterich, DT | 1 |
| Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH | 1 |
| Dvorchik, I; Eghtesad, B; Fontes, PA; Fung, JJ; Jain, AB; Kashyap, R; Kingery, L; Shakil, AO; Venkataramanan, R | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Hu, R; Ibrahim, AB; Kunder, G; Lassman, C; Saab, S; Yersiz, H | 1 |
| Del Vecchio, C; Durante Mangoni, E; Marrone, A; Ruggiero, G; Saviano, D; Utili, R | 1 |
| Fouchard-Hubert, I; Gergely, AE; Lunel-Fabiani, F | 1 |
| Sulkowski, MS | 2 |
| Dev, A; McHutchison, JG; Muir, A; Patel, K | 1 |
| Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R | 1 |
| Afdhal, NH | 1 |
| Bräu, N | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, T; Younossi, Z | 1 |
| Agarwal, K; Dieterich, DT; Kontorinis, N | 1 |
| Trivedi, HS; Trivedi, M | 1 |
| Ong, JP; Younossi, ZM | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Kostman, JR; Lo Re, V | 1 |
| Chung, RT; Yachimski, P | 1 |
| Afdhal, NH; Bowers, PJ; Dieterich, DT; Goon, BL; Leitz, G; Mody, SH; Pockros, PJ; Schiff, ER; Shiffman, ML; Sulkowski, MS; Tang, KL; Wright, TL; Younossi, Z | 1 |
| Kowdley, KV | 1 |
| Collantes, RS; Younossi, ZM | 1 |
| Ascher, NA; Bollinger, K; Khalili, M; Roberts, JP; Shergill, AK; Straley, S; Terrault, NA | 1 |
| Balan, V; Bowers, PJ; Burnett, A; Ghalib, R; Goon, BL; Jackson, J; Keeffe, EB; Leitz, GJ; Muir, AJ; Rossaro, L; Schwartz, D; Wu, GY | 1 |
| Chawla, S; Rivkin, AM | 1 |
| Motoo, Y; Mouri, H; Ohtsubo, K; Sawabu, N; Watanabe, H; Yamaguchi, Y | 1 |
| Alvarez, D; Bini, EJ; Bräu, N; Dejesus, E; Dieterich, DT; Leitz, GJ; Sulkowski, MS | 1 |
| Fung, J; Jain, A; Kashyap, R; Marcos, A; Vekatramanan, R; Yelochan, B | 1 |
| Broissand, C; Fontaine, H; Lebray, P; Nalpas, B; Pol, S; Serpaggi, J; Sobesky, R; Vallet-Pichard, A | 1 |
| Chen, K; Chiou, CF; Robbins, S; Spiegel, BM; Younossi, ZM | 1 |
| Boyanova, Y; Calmus, Y; Conti, F; Pissaia, A; Soubrane, O | 1 |
| Stadlbauer, V; Stauber, RE | 1 |
| Becker, MC; Bresson-Hadni, S; Bronowicki, JP; Di Martino, V; Lunel-Fabiani, F; Miguet, JP; Thevenot, T; Vanlemmens, C | 1 |
| Cohen, L; Cooper, MA; Elkashab, M; Feinman, V; Fletcher, D; Girgrah, N; Heathcote, J; Levstik, M; McNaull, WB; Sherman, M; Wong, D; Wong, F; Yim, C | 1 |
| Dar Santos, A; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Dolmazashvili, E; Gochitashvili, N; Kakabadze, T; Sharvadze, L; Tsertsvadze, T | 1 |
| Agyemang, AF; Hu, Z; Kottilil, S; McLaughlin, MM; Pau, AK; Polis, MA | 1 |
| Ferenci, P; Formann, E; Gangl, A; Homoncik, M; Jilma, B; Peck-Radosavljevic, M; Schmid, M; Sieghart, W | 1 |
| McHutchison, JG; Muir, AJ | 1 |
| Del Rio, RA; Post, AB; Singer, ME | 1 |
| Grattagliano, I; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S | 1 |
| Bowers, P; Henry, DH; Lamarca, A; Leitz, G; Slim, J | 1 |
| Dar Santos, AE; Ford, JA; Partovi, N; Yoshida, EM | 1 |
| Leiner, S | 1 |
| Brown, RS; Manns, MP; McHutchison, JG; Reddy, KR; Shiffman, ML; Wong, JB | 1 |
| Cuadrado Pastor, JM; Jover Díaz, FM; Wikman Jorgensen, PE | 1 |
| Bosch, J; Bruguera, M; Carrión, JA; Crespo, G; Forns, X; García-Pagan, JC; García-Retortillo, M; Navasa, M | 1 |
| Hubbard, S; Luketic, VA; Price, A; Salvatore, J; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Cross, JT; Devine, EB; Kowdley, KV; Sullivan, SD | 1 |
| Alobeid, B; Gaglio, PJ; Mears, JG; Schecter, JM | 1 |
| Bai, C; Collantes, R; Fang, Y; Farmer, D; Gujral, H; Gurung, C; Nader, FH; Ong, JP; Ramsey, L; Sjogren, M; Sjogren, R; Srishord, M; Terra, K; Younossi, ZM | 1 |
| De Tullio, D; Falasca, K; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Bourliere, M | 1 |
| Esposito, L; Guitard, J; Kamar, N; Ribes, D; Rostaing, L | 1 |
| Gomollón García, F; Moreno López, R; Sicilia Aladrén, B | 1 |
| Callender, ME; Cash, WJ; McDougall, NI; Patterson, K | 1 |
| Falasca, K; Gorgoretti, V; Mancino, P; Pizzigallo, E; Ucciferri, C; Vecchiet, J | 1 |
| Mac Nicholas, R; Norris, S | 1 |
| Cardona-Meléndez, GM; DebRoy, S; Diaz, E; Kang, M; Kribs-Zaleta, C; Medina-Rios, L; Mubayi, A | 1 |
| Aguirrebengoa, K; Barreiro, P; Guardiola, JM; Labarga, P; Miralles, C; Miralles, P; Morello, J; Portu, J; Rodriguez-Novoa, S; Rubio, R; Soriano, V; Vispo, E | 1 |
| Cozma, A; Orāşan, O; Pârvu, A; Petrov, L; Rednic, N; Sâmpelean, D | 1 |
| Ardiri, A; Bertino, G; Boemi, PM; Boemi, R; Bruno, CM; Calvagno, GS; Ierna, D; Naimo, S; Neri, S; Ruggeri, IM; Santonocito, MM; Speranza, A; Valenti, M | 1 |
| Black, M; Burke, M; Jain, AB; Singhal, A | 1 |
| Boland, GJ; Burger, DM; Drenth, JP; Janssen, MP; Siersema, PD; Van Erpecum, KJ; Van Soest, H; Van Vlerken, LG | 1 |
| Cabrera, R; Draganov, PV; Limaye, AR | 1 |
| Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M | 1 |
| Attili, AF; Biliotti, E; Corradini, SG; Gentili, F; Giannelli, V; Giusto, M; Lionetto, L; Merli, M; Rossi, M; Simmaco, M; Taliani, G | 1 |
| De Gottardi, A; Geier, A; Gerlach, T; Heim, M; Helbling, B; Hirschi, C; Negro, F; Stickel, F; Terziroli, B; Wehr, K | 1 |
| Alavian, SM; Behnava, B; Tabatabaei, SV | 1 |
| Abbott, D; Lee, HK; Trask, LE | 1 |
| Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakamoto, N; Sho, T; Terashita, K | 1 |
| Bae, SH; Jun, DW; Lee, YJ; Tak, WY | 1 |
| Ackefors, M; Gjertsen, H; Weiland, O; Wernerson, A | 1 |
| Afdhal, NH; Albrecht, JK; Brass, CA; Bronowicki, JP; Burroughs, MH; Harrison, SA; Jacobson, IM; Koury, KJ; Manns, MP; Pedicone, LD; Poordad, F; Rajender Reddy, K; Sings, HL; Sniukiene, V; Sulkowski, MS | 1 |
| Tai, YK; Tsai, CY; Wu, CS | 1 |
| Heil, EL; Hynicka, LM | 1 |
| Boonstra, A; De Knegt, RJ; Groothuismink, ZM; Janssen, HL; Koning, L; Roomer, R; Spaan, M | 1 |
| Berenguer, M; Calleja, JL; Molina, E; Romero-Gómez, M | 1 |
| Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S | 1 |
| Alsaran, K; Molhem, A; Sabry, A | 1 |
| Pol, S | 1 |
| Beste, LA; Green, PK; Ioannou, GN; Scott, JD; Yang, Y | 1 |
| Alonso, S; Bárcena, R; Calleja, JL; Casanovas, T; Fernández-Rodríguez, CM; González, JM; Jorquera, F; Martín-Martín, L; Masnou, H; Miquel-Planas, M; Morillas, RM; Navarro, JM; Planas, R; Poyato, A; Romero-Gomez, M; Salmerón, J; Solà, R | 1 |
| Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Lee, CY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML | 1 |
| Amanzada, A; Cameron, S; Goralczyk, AD; Mihm, S; Moriconi, F; Reinhardt, L | 1 |
| Gattei, V; Mauro, E; Mazzaro, C | 1 |
| Boyer-Darrigand, N; D'alteroche, L; Dao, MT; Ducancelle, A; Fouchard-Hubert, I; Larrey, D; Le Guillou-Guillemette, H; Loustaud-Ratti, V; Lunel-Fabiani, F; Picard, N; Saulnier, P; Veillon, P | 1 |
24 review(s) available for ribavirin and losartan potassium
| Article | Year |
|---|---|
Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin | 2002 |
Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin.
Topics: Antiviral Agents; Chemotherapy, Adjuvant; Drug Therapy, Combination; Erythropoietin; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Severity of Illness Index; Treatment Outcome; Viral Load | 2004 |
Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukin-11; Neutropenia; Patient Compliance; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
Anemia during treatment of hepatitis C in HIV-infected patients.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Hematologic side effects of interferon and ribavirin therapy.
Topics: Anemia, Hypochromic; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
Topics: Anemia, Hypochromic; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematinics; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Health Care Costs; Hepatitis C; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin; Risk Factors | 2005 |
Management of the hematologic complications of hepatitis C therapy.
Topics: Anemia; Antiviral Agents; Bone Marrow; Epoetin Alfa; Erythropoietin; Hematologic Diseases; Hepatitis C, Chronic; Humans; Interferon Type I; Neutropenia; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2005 |
Novel approaches for therapy of chronic hepatitis C.
Topics: Antidepressive Agents; Antiviral Agents; Clinical Trials as Topic; Erythropoietin; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Protease Inhibitors; Purine-Nucleoside Phosphorylase; Pyrimidine Nucleosides; Ribavirin; Viral Hepatitis Vaccines | 2006 |
[Complementary treatments of chronic viral hepatitis C].
Topics: Anemia; Antidepressive Agents; Antioxidants; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin.
Topics: Algorithms; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.
Topics: Anemia; Antiviral Agents; Erythropoietin; Humans; Oxidants; Ribavirin; Risk Factors | 2006 |
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Topics: Anemia; Chemotherapy, Adjuvant; Epoetin Alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; Humans; Interferons; MEDLINE; Neutropenia; Recombinant Proteins; Ribavirin | 2007 |
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Quality of Life; Recombinant Proteins; Ribavirin | 2007 |
Use of agents stimulating erythropoiesis in digestive diseases.
Topics: Anemia; Erythropoiesis; Erythropoietin; Hematinics; Hepatitis C; Humans; Inflammatory Bowel Diseases; Ribavirin | 2009 |
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia; Viral Load | 2010 |
Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2009 |
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
Topics: Anemia; Antiviral Agents; Erythropoietin; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Outcome | 2012 |
Recent trends in the treatment of chronic hepatitis C.
Topics: Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Precision Medicine; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral | 2012 |
Anemia management in patients with chronic viral hepatitis C.
Topics: Anemia; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Hematinics; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Ribavirin; Risk Factors; Serine Proteinase Inhibitors; Viral Nonstructural Proteins | 2013 |
Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.
Topics: Anemia; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin | 2013 |
30 trial(s) available for ribavirin and losartan potassium
| Article | Year |
|---|---|
A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha.
Topics: Anemia; Antiviral Agents; Erythropoietin; Humans; Interferon-alpha; Pilot Projects; Prospective Studies; Ribavirin | 2001 |
Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Ribavirin | 2002 |
[Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C].
Topics: Adenosine Triphosphate; Anemia; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Glutathione; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reticulocyte Count; Ribavirin | 2003 |
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Probability; Recombinant Proteins; Reference Values; Ribavirin; Treatment Outcome | 2003 |
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Function Tests; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin; Viral Load | 2004 |
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2004 |
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Growth Substances; Hepatitis C; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Interferons; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Prednisone; Recombinant Proteins; Ribavirin; Tacrolimus; Time Factors | 2005 |
Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: a randomized controlled trial.
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Herbal Medicine; Humans; Liver Function Tests; Male; Middle Aged; Plant Extracts; Ribavirin; Th1 Cells; Th2 Cells; Viral Load | 2005 |
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anemia; Antiviral Agents; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Quality of Life; Recombinant Proteins; Ribavirin | 2005 |
Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection.
Topics: Adult; Aged; Antiviral Agents; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recombinant Proteins; Ribavirin; Treatment Outcome | 2006 |
Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Administration Schedule; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2006 |
Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
Topics: Adult; Antiviral Agents; Blood Cell Count; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; P-Selectin; Polyethylene Glycols; Receptor, PAR-1; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2006 |
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Darbepoetin alfa; Disease Progression; Dose-Response Relationship, Drug; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Portal Pressure; Recombinant Proteins; Ribavirin; Secondary Prevention | 2007 |
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
Topics: Adult; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral | 2007 |
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
Topics: Adult; Anemia; Antiviral Agents; Darbepoetin alfa; Erythropoietin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
Topics: Anemia; Antiviral Agents; Chronic Disease; Creatinine; Darbepoetin alfa; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Liver Transplantation; Male; Pilot Projects; Postoperative Care; Prospective Studies; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Epoetin Alfa; Erythrocytes; Erythropoietin; Female; Hematinics; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
Topics: Adult; Anemia, Hypochromic; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Ferritins; Hematinics; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anemia; Antiviral Agents; Biomarkers; Creatinine; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Linear Models; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2011 |
Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.
Topics: Adult; Aged; Anemia; Antiviral Agents; Erythropoietin; Female; Genotype; Hemoglobins; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Platelet Count; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Thrombocytosis | 2012 |
Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Darbepoetin alfa; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematinics; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Treatment Outcome | 2013 |
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
Topics: Algorithms; Anemia; Antiviral Agents; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Topics: Adult; Antiviral Agents; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Renal Dialysis; Ribavirin; Saudi Arabia | 2013 |
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Viremia | 2014 |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Topics: Adult; Aged; Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Erythropoietin; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
36 other study(ies) available for ribavirin and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemolysis; Hepatitis C; Humans; Interferon-alpha; Kidney; Liver; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin | 2002 |
Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Erythropoietin; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2003 |
Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Biological; Recombinant Proteins; Ribavirin | 2003 |
Anemia in the treatment of hepatitis C virus infection.
Topics: Anemia; Antiviral Agents; Epoetin Alfa; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2003 |
Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions.
Topics: Anemia, Hemolytic; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Male; Prognosis; Ribavirin; Treatment Outcome | 2003 |
Role of epoetin alfa in maintaining ribavirin dose.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Hematinics; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Thrombocytopenia | 2004 |
Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C.
Topics: Adult; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Hematocrit; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Recombinant Proteins; Ribavirin | 2004 |
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
Topics: Anemia; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2005 |
The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2005 |
Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
Topics: Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Darbepoetin alfa; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2005 |
[Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number.
Topics: Antiviral Agents; Chemotherapy, Adjuvant; Erythropoietin; Hepacivirus; Hepatitis C; Humans; Interferons; Recombinant Proteins; Ribavirin | 2006 |
Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Topics: Algorithms; Antiviral Agents; Cost-Benefit Analysis; Erythropoietin; Hepatitis C, Chronic; Humans; Intercellular Signaling Peptides and Proteins; Randomized Controlled Trials as Topic; Ribavirin; Treatment Outcome | 2006 |
Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy.
Topics: Anemia; Cost-Benefit Analysis; Darbepoetin alfa; Decision Trees; Drug Therapy, Combination; Erythropoietin; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Markov Chains; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin | 2006 |
Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
Topics: Adolescent; Adult; Aged; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Black People; Cell Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Female; Hemoglobins; Hepatitis C, Chronic; Hispanic or Latino; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Protease Inhibitors; Recombinant Proteins; Reticulocytes; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors; Treatment Outcome; White People; Zidovudine | 2007 |
Peginterferon and ribavirin for hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2007 |
[Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Topics: Adult; Antiviral Agents; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Iron; Male; Pancytopenia; Polyethylene Glycols; Receptor, Interferon alpha-beta; Recombinant Proteins; Ribavirin; Signal Transduction | 2007 |
The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Topics: Algorithms; Anemia; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Erythropoietin; Genotype; Health Care Costs; Health Resources; Hepatitis C; Humans; Models, Theoretical; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
Topics: Anemia; Antibodies; Antiviral Agents; Epoetin Alfa; Erythropoietin; Graft Rejection; Hematinics; Hepatitis C; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Mycophenolic Acid; Polyethylene Glycols; Prednisone; Recombinant Proteins; Red-Cell Aplasia, Pure; Ribavirin; Secondary Prevention; Tacrolimus | 2007 |
High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Topics: Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Erythropoietin; Female; Hematocrit; Hemoglobins; Hepatitis C; Humans; Middle Aged; Recombinant Proteins; Ribavirin | 2007 |
[Treatment of hepatitis C: therapeutic management].
Topics: Anemia; Antiviral Agents; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferons; Middle Aged; Ribavirin | 2008 |
Adjuvant therapy used in conjunction with combination therapy for chronic hepatitis C improves sustained virus response rates in genotype 1 patients.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Erythropoietin; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Evaluating treatment of hepatitis C for hemolytic anemia management.
Topics: Anemia, Hemolytic; Antiviral Agents; Computer Simulation; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Models, Biological; Recombinant Proteins; Ribavirin | 2010 |
Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
Topics: Adult; Antiviral Agents; Blood Transfusion; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hematinics; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pennsylvania; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Boceprevir for chronic HCV genotype 1 infection.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2011 |
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Pilot Projects; Premedication; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2011 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; Insulin Glargine; Insulin, Long-Acting; Interferon-alpha; Metformin; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2012 |
Combination effect of ribavirin and erythropoietin treatment on hemoglobin A1c in a diabetic patient with chronic hepatitis C.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin | 2012 |
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.
Topics: Anemia; Erythropoietin; Escherichia coli; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukin-6; Ligands; Lipopolysaccharides; Monocytes; Phagocytosis; Reactive Oxygen Species; Receptors, Erythropoietin; Ribavirin; RNA, Messenger; Toll-Like Receptor 4 | 2013 |
HCV, ribavirin, and anemia: a new dawn.
Topics: Anemia; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin | 2013 |
Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Erythropoietin; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
Topics: Adult; Alleles; Antiviral Agents; Down-Regulation; Epoetin Alfa; Erythropoietin; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2014 |
Recombinant Human Erythropoietin (RHuEpo) and Granular Colony Stimulating Factor (G-CSF) in hepatitis C virus (HCV) related to mixed cryoglobulinaemia associated to membranoproliferative glomerulonephritis type I: a case report description.
Topics: Anemia; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Erythropoietin; Glomerulonephritis, Membranoproliferative; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Neutropenia; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Outcome | 2014 |